产品
编 号：F387910
分子式：C17H14O7
分子量：330.29
分子式：C17H14O7
分子量：330.29
产品类型
规格
价格
是否有货
结构图
CAS No: 552-54-5
产品详情
生物活性：
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.
体内研究：
Rhamnazin (200 mg/kg; i.g.; daily for 25 days) 抑制小鼠乳腺癌生长和血管生成。Rhamnazin (5-20 mg/kg; i.p.; once) 在大鼠急性肺损伤模型中显示出较强的抗氧化和抗炎作用。Animal Model:BALB/c nude mice, breast cancer xenograft model
Dosage:200 mg/kg
Administration:Intragastric administration, daily for 25 days
Result:Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3.
体外研究：
Rhamnazin (5-40 μM) 抑制 VEGF 诱导的 HUVECs 增殖、迁移和成管。Rhamnazin (0-20 μM) 降低 VEGFR-2 酪氨酸激酶活性和 VEGFR-2 信号通路。Rhamnazin (0-40 μM; 24 h) 抑制乳腺癌细胞增殖和 VEGFR2 信号通路。
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.
体内研究：
Rhamnazin (200 mg/kg; i.g.; daily for 25 days) 抑制小鼠乳腺癌生长和血管生成。Rhamnazin (5-20 mg/kg; i.p.; once) 在大鼠急性肺损伤模型中显示出较强的抗氧化和抗炎作用。Animal Model:BALB/c nude mice, breast cancer xenograft model
Dosage:200 mg/kg
Administration:Intragastric administration, daily for 25 days
Result:Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3.
体外研究：
Rhamnazin (5-40 μM) 抑制 VEGF 诱导的 HUVECs 增殖、迁移和成管。Rhamnazin (0-20 μM) 降低 VEGFR-2 酪氨酸激酶活性和 VEGFR-2 信号通路。Rhamnazin (0-40 μM; 24 h) 抑制乳腺癌细胞增殖和 VEGFR2 信号通路。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备